A Viral Testing Facility – Striving For Excellence

As biologics continue to drive growth in the biopharmaceutical industry, ensuring viral safety has become a critical requirement for successful drug development and commercialization. Every biologic product must undergo rigorous testing to confirm the absence of viral contaminants and demonstrate the robustness of manufacturing processes.

Syngene’s viral testing facility plays a key role in meeting these demands, offering globally compliant services backed by GLP certification in line with OECD standards. This ensures that studies conducted at the facility are accepted by regulatory authorities in major markets, including the United States and Japan.

The facility supports a range of services, including cell bank testing, bulk harvest analysis, and virus clearance studies, all designed to verify product safety and process reliability. By combining testing with orthogonal clearance strategies, manufacturers can confidently mitigate viral risks throughout production.

Through continuous quality improvements and a strong focus on compliance, the facility helps biopharma companies advance therapies safely from development to commercialization.